MedTrace Logo

Study of Different Doses of a Novel Treatment for Onychomycosis

NCT00679965 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2018-12-12

No results posted yet for this study

Summary

The purpose of the study is to determine the safety and efficacy of 2.5%, 5.0%, and 7.5% AN2690 Solutions compared to the vehicle alone in the treatment of distal, subungual onychomycosis of the great target toenail.

Conditions

  • Distal, Subungual Onychomycosis

Interventions

DRUG

AN2690, 2.5%

Once daily application for 90 days and 3 x weekly for 90 days

DRUG

AN2690, 5%

Once daily application for 90 days and 3 x weekly for 90 days

DRUG

AN2690, 7.5%

Once daily application for 90 days and 3 x weekly for 90 days

DRUG

AN2690 Solution Vehicle

Once daily application for 90 days and 3x weekly for 90 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00679965 on ClinicalTrials.gov